Skip to main content
AAN.com

Abstract

Background: Increased homocysteine levels might accelerate dopaminergic cell death in Parkinson disease (PD), through neurotoxic effects. Higher dietary intakes of folate, vitamin B12, and vitamin B6 (cofactors in homocysteine metabolism) might decrease the risk of PD through decreasing plasma homocysteine. Moreover, vitamin B6 might influence the risk of PD through antioxidant effects unrelated to homocysteine metabolism and through its role in dopamine synthesis.
Methods: In the Rotterdam Study, a prospective, population-based cohort study of people aged 55 years and older, the authors evaluated the association between dietary intake of folate, vitamin B12, and vitamin B6 and the risk of incident PD among 5,289 participants who were free of dementia and parkinsonism and underwent complete dietary assessment at baseline. PD was assessed through repeated in-person examination and continuous monitoring by computer linkage to medical records. Data were analyzed using Cox proportional hazards regression analysis.
Results: After a mean follow-up of 9.7 years, the authors identified 72 participants with incident PD. Higher dietary intake of vitamin B6 was associated with a significantly decreased risk of PD (hazard ratio per SD, 0.69 [95% CI 0.50 to 0.96]; for highest vs lowest tertile, 0.46 [0.22 to 0.96]). Stratified analyses showed that this association was restricted to smokers. No association was observed for dietary folate and vitamin B12.
Conclusions: Dietary vitamin B6 may decrease the risk of Parkinson disease, probably through mechanisms unrelated to homocysteine metabolism.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Greenamyre JT, Hastings TG. Biomedicine: Parkinson’s—divergent causes, convergent mechanisms. Science 2004;304:1120–1122.
2.
Jenner P. Oxidative stress in Parkinson’s disease. Ann Neurol 2003;53 (suppl 3):S26–S36.
3.
Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson’s disease. J Neurochem 2002;80:101–110.
4.
Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 2000;20:6920–6926.
5.
Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson’s disease. Eur Neurol 1998;40:225–227.
6.
Muller T, Werne B, Fowler B, Kuhn W. Nigral endothelial dysfunction, homocysteine, and Parkinson’s disease. Lancet 1999;354:126–127.
7.
Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437–440.
8.
de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005;57:927–930.
9.
Refsum H, Smith AD, Ueland PM, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3–32.
10.
Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–2698.
11.
Selhub J, Jacques PF, Rosenberg IH, et al. Serum total homocysteine concentrations in the third National Health and Nutrition Examination Survey: 1991-1994 population reference ranges and contribution of vitamin status to high serum concentrations. Ann Intern Med 1999;131:331–339.
12.
Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363–375.
13.
Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Ann Rev Med 1998;49:31–62.
14.
Mahfouz MM, Kummerow FA. Vitamin C or vitamin B6 supplementation prevent the oxidative stress and decrease of prostacyclin generation in homocysteinemic rats. Int J Biochem Cell Biol 2004;36:1919–1932.
15.
Kannan K, Jain SK. Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H2O2-treated U937 monocytes. Free Radic Biol Med 2004;36:423–428.
16.
Chumnantana R, Yokochi N, Yagi T. Vitamin B6 compounds prevent the death of yeast cells due to menadione, a reactive oxygen generator. Biochim Biophys Acta 2005;1722:84–91.
17.
Jain SK, Lim G. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic Biol Med 2001;30:232–237.
18.
Cabrini L, Bergami R, Fiorentini D, Marchetti M, Landi L, Tolomelli B. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int 1998;46:689–697.
19.
Stocker P, Lesgards JF, Vidal N, Chalier F, Prost M. ESR study of a biological assay on whole blood: antioxidant efficiency of various vitamins. Biochim Biophys Acta 2003;1621:1–8.
20.
Dakshinamurti K, Paulose CS, Viswanathan M, Siow YL, Sharma SK, Bolster B. Neurobiology of pyridoxine. Ann NY Acad Sci 1990;585:128–144.
21.
Tan EK, Cheah SY, Fook-Chong S, et al. Functional COMT variant predicts response to high dose pyridoxine in Parkinson’s disease. Am J Med Genet B Neuropsychiatr Genet 2005;137:1–4.
22.
Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403–422.
23.
de Lau LM, Giesbergen PC, de Rijk MC, Hofman A, Koudstaal PJ, Breteler MM. Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study. Neurology 2004;63:1240–1244.
24.
Fahn S, Members of the UPDRS Development Committee. Unified Parkinson’s Disease Rating Scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent developments in Parkinson’s disease. Florham Park: MacMillan Healthcare Information, 1987:153–163.
25.
Klipstein-Grobusch K, den Breeijen JH, Goldbohm RA, et al. Dietary assessment in the elderly: validation of a semiquantitative food frequency questionnaire. Eur J Clin Nutr 1998;52:588–596.
26.
Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432–1437.
27.
Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613–621.
28.
Quik M. Smoking, nicotine and Parkinson’s disease. Trends Neurosci 2004;27:561–568.
29.
Chen H, Zhang SM, Schwarzschild MA, et al. Folate intake and risk of Parkinson’s disease. Am J Epidemiol 2004;160:368–375.
30.
Diaz-Arrastia R. Homocysteine and neurologic disease. Arch Neurol 2000;57:1422–1427.

Information & Authors

Information

Published In

Neurology®
Volume 67Number 2July 25, 2006
Pages: 315-318
PubMed: 16864826

Publication History

Published online: July 24, 2006
Published in print: July 25, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

L.M.L. de Lau, MD, PhD
From the Department of Epidemiology & Biostatistics (L.M.L.d.L., J.C.M.W., A.H., M.M.B.B.) and Department of Neurology (L.M.L.d.L., P.J.K.), Erasmus Medical Center, Rotterdam, The Netherlands.
P. J. Koudstaal, MD, PhD
From the Department of Epidemiology & Biostatistics (L.M.L.d.L., J.C.M.W., A.H., M.M.B.B.) and Department of Neurology (L.M.L.d.L., P.J.K.), Erasmus Medical Center, Rotterdam, The Netherlands.
J. C.M. Witteman, PhD
From the Department of Epidemiology & Biostatistics (L.M.L.d.L., J.C.M.W., A.H., M.M.B.B.) and Department of Neurology (L.M.L.d.L., P.J.K.), Erasmus Medical Center, Rotterdam, The Netherlands.
A. Hofman, MD, PhD
From the Department of Epidemiology & Biostatistics (L.M.L.d.L., J.C.M.W., A.H., M.M.B.B.) and Department of Neurology (L.M.L.d.L., P.J.K.), Erasmus Medical Center, Rotterdam, The Netherlands.
M. M.B. Breteler, MD, PhD
From the Department of Epidemiology & Biostatistics (L.M.L.d.L., J.C.M.W., A.H., M.M.B.B.) and Department of Neurology (L.M.L.d.L., P.J.K.), Erasmus Medical Center, Rotterdam, The Netherlands.

Notes

Address correspondence and reprint requests to Dr. Monique M.B. Breteler, Department of Epidemiology & Biostatistics, Erasmus Medical Center, PO Box 1738, 3000 DR Rotterdam, The Netherlands; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Natural Bioactive Products as Epigenetic Modulators for Treating Neurodegenerative Disorders, Pharmaceuticals, 16, 2, (216), (2023).https://doi.org/10.3390/ph16020216
    Crossref
  2. Bioinorganic Chemistry of Micronutrients Related to Alzheimer’s and Parkinson’s Diseases, Molecules, 28, 14, (5467), (2023).https://doi.org/10.3390/molecules28145467
    Crossref
  3. Could Vitamins Have a Positive Impact on the Treatment of Parkinson’s Disease?, Brain Sciences, 13, 2, (272), (2023).https://doi.org/10.3390/brainsci13020272
    Crossref
  4. Association between the risk and severity of Parkinson’s disease and plasma homocysteine, vitamin B12 and folate levels: a systematic review and meta-analysis, Frontiers in Aging Neuroscience, 15, (2023).https://doi.org/10.3389/fnagi.2023.1254824
    Crossref
  5. The role of dietary antioxidants in type 2 diabetes and neurodegenerative disorders: An assessment of the benefit profile, Heliyon, 9, 1, (e12698), (2023).https://doi.org/10.1016/j.heliyon.2022.e12698
    Crossref
  6. Phytoconstituents-based nanoformulations for neurodegenerative disorders, Recent Frontiers of Phytochemicals, (463-482), (2023).https://doi.org/10.1016/B978-0-443-19143-5.00003-7
    Crossref
  7. Lifestyle modifications and nutrition in Alzheimer's disease, Diet and Nutrition in Neurological Disorders, (13-39), (2023).https://doi.org/10.1016/B978-0-323-89834-8.00049-0
    Crossref
  8. Metformin role in Parkinson’s disease: a double-sword effect, Molecular and Cellular Biochemistry, (2023).https://doi.org/10.1007/s11010-023-04771-7
    Crossref
  9. Parkinson’s Disease Risk and Hyperhomocysteinemia: The Possible Link, Cellular and Molecular Neurobiology, 43, 6, (2743-2759), (2023).https://doi.org/10.1007/s10571-023-01350-8
    Crossref
  10. Homocysteine, vitamin B metabolites, dopamine-substituting compounds, and symptomatology in Parkinson’s disease: clinical and therapeutic considerations, Journal of Neural Transmission, 130, 11, (1451-1462), (2023).https://doi.org/10.1007/s00702-023-02684-9
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share